Drug Trial Radar · NCT02727803
Personalized NK Cell Therapy in CBT
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
May 19, 2016
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Apr 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.
Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Acute Biphenotypic Leukemia
- Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia in Remission
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Acute Myeloid Leukemia With Variant MLL Translocations
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Chemotherapy-Related Leukemia
- Chronic Myelomonocytic Leukemia
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- ISS Stage II Plasma Cell Myeloma
- ISS Stage III Plasma Cell Myeloma
- Myelodysplastic Syndrome
- Myelodysplastic Syndrome With Excess Blasts
- Myelodysplastic Syndrome With Gene Mutation
- Myelodysplastic/Myeloproliferative Neoplasm
- Previously Treated Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Hodgkin Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Refractory Acute Lymphoblastic Leukemia
- Refractory Adult Acute Lymphoblastic Leukemia
- Secondary Acute Myeloid Leukemia
- Therapy-Related Myelodysplastic Syndrome
Interventions
Allogeneic Natural Killer Cell Line NK-92Biological
Given IV
Anti-Thymocyte GlobulinBiological
Given IV
BusulfanDrug
Given IV
ClofarabineDrug
Given IV
CyclophosphamideDrug
Given IV
Fludarabine PhosphateDrug
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
MelphalanDrug
Given IV
RituximabBiological
Given IV
Total-Body IrradiationRadiation
Undergo total body irradiation
Umbilical Cord Blood TransplantationProcedure
Undergo umbilical cord blood transplantation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS) time in C2C2 patientsTime frame: From the date of engraftment to disease progression or death, assessed up to 4 years
- Progression free survival (PFS) time in C1 patientsTime frame: From the date of cord blood transplant to disease progression or death, assessed up to 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
M D Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.